Related Experiment Video
Updated: Jun 6, 2026
04:32
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Multi-drug resistant Acinetobacter ventilator-associated pneumonia.
Vishal B Shete1, Dnyaneshwari P Ghadage, Vrishali A Muley
1Department of Microbiology, BJ Medical College and Sassoon General Hospital, Pune, India.
Lung India : Official Organ of Indian Chest Society
|December 9, 2010
Summary
Multi-drug resistant Acinetobacter causes ventilator-associated pneumonia (VAP) in ICUs. This study found an 11.6% incidence of Acinetobacter VAP, linked to head injuries, cerebral hemorrhage, and COPD, highlighting the need for strict infection control.
Area of Science:
- Critical care medicine
- Infectious diseases
- Microbiology
Background:
- Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Acinetobacter is a significant challenge in intensive care units (ICUs).
- Acinetobacter infections in VAP cases require thorough investigation due to their severity and resistance patterns.
Purpose of the Study:
- To determine the incidence of Acinetobacter infection in VAP cases.
- To identify risk factors associated with Acinetobacter acquisition in VAP patients.
- To analyze the antimicrobial susceptibility patterns of Acinetobacter strains.
Main Methods:
- Bacteriological analysis of 60 endotracheal aspirate specimens from intubated patients diagnosed with VAP.
- Collection of clinical details and antibiotic exposure history for all patients.
Main Results:
- An incidence of 11.6% for Acinetobacter VAP was recorded.
- Underlying conditions such as head injury, cerebral hemorrhage, and chronic obstructive pulmonary disease (COPD) were associated with Acinetobacter VAP.
- Acinetobacter strains demonstrated a multidrug-resistant (MDR) pattern.
Conclusions:
- Strict infection control measures are crucial for managing Acinetobacter VAP.
- Judicious antibiotic prescribing, resistance surveillance, and antibiotic cycling are recommended strategies.
- Implementing these measures can help control Acinetobacter infections in ICU patients.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:30Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:21Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:21Acute Respiratory Failure-I
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...